ASCO relevanceLooking for grizzled veterans of this story. Are there additional discussion sites? Also posted on Stocktwits.
This ASCO presentation may spark a change in sentiment about the company. Seems like a good time to discuss ONCY if there is actual work being done on the story. You don't want to get over your skis on this ASCO presentation. BRACELET is a 3-arm trial with 15 patients in each - not designed to reveal a reliable survival outcome but powered to inform about response rate and immune impact. BRACELET has excluded ER- breast cancer patients - a group with no demonstrated response. The abstract was approved for presentation with data from NOV 2022; the ASCO data will be updated by 6 months. If the MAY 2023 BRACELET data confirm the results of the 57 ER+ patients in the IND213 trial (~30 Reo treated patients in BRACELET and IND213), the company negotiates with a partner and the FDA for a Ph III registration trial. If the updated BRACELET results are lukewarm, the breast indication is eliminated.